Cargando…
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angi...
Autores principales: | Wang, James Jiqi, Edin, Matthew L., Zeldin, Darryl C., Li, Chenze, Wang, Dao Wen, Chen, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346797/ https://www.ncbi.nlm.nih.gov/pubmed/32653530 http://dx.doi.org/10.1016/j.pharmthera.2020.107628 |
Ejemplares similares
-
The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023) -
Adenosine and the Cardiovascular System: The Good and the Bad
por: Guieu, Régis, et al.
Publicado: (2020) -
Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021) -
Physical activity, COVID-19, and respiratory comorbidities: The good, the bad, and the ugly
por: Dinh-Xuan, Anh-Tuan, et al.
Publicado: (2023) -
The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)